top of page
![](https://static.wixstatic.com/media/11062b_1c71479cd09d4df2958ef7b728855282~mv2_d_4965_3456_s_4_2.jpg/v1/fill/w_288,h_200,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/11062b_1c71479cd09d4df2958ef7b728855282~mv2_d_4965_3456_s_4_2.jpg)
July 2020 : Vedolizumab launched in India
![1.png](https://static.wixstatic.com/media/948dd7_7b88438bac744eb08734cc61ff71b9ac~mv2.png/v1/crop/x_0,y_0,w_204,h_289/fill/w_286,h_403,al_c,lg_1,q_85,enc_auto/1.png)
• First biologic other than anti-TNFs launched in India
• Vedolizumab, a gut-specific anti-integrin is found to have a lower risk of activation of latent tuberculosis and other infections which is important an Indian perspective
​
• An additional biologic in the armamentarium of IBD management as anti-TNF failures are increasingly being recognized
bottom of page